To observe the effects of Guizhi Fuling Capsules on the postoperative recovery and levels of inflammatory mediators in patients with early endometrial cancer after laparoscopy.Methods:Eighty patients with early endometrial cancer treated at Xuzhou Central Hospital from June 2019 to May 2022 were enrolled and randomly divided into an observation group and a control group，with 40 cases in each group.The control group received laparoscopy，while the observation group received postoperative treatment with Guizhi Fuling Capsules，3 capsules per time，3 times a day，taken orally after meals for 3 months.The disease remission rate，postoperative recovery [Visual Analogue Scale(VAS) scores at 1，3，and 7 days postoperatively，bladder function recovery time，and length of hospital stay]，traditional Chinese medicine(TCM) syndrome scores，and related serum indicators [cancer antigen(CA) 125，human epididymis protein 4(HE4)，interleukin-4(IL-4)，and IL-6] before surgery and 3 months after surgery，as well as the incidence of postoperative complications，were compared between the two groups.Results:The total disease remission rate in the observation group was 90.00%，higher than that in the control group(72.50%)(P<0.05).The VAS scores at 3 and 7 days postoperatively were lower in the observation group than in the control group，and the bladder function recovery time and length of hospital stay were shorter in the observation group(all P<0.05).Three months after surgery，the TCM syndrome scores in the observation group were lower than those in the control group(all P<0.05)，and the serum levels of CA125，HE4，and IL-6 were lower in the observation group(all P<0.05)，while the IL-4 level was higher than that in the control group(P<0.05).There was no significant difference in the incidence of postoperative complications between the two groups(P>0.05).Conclusion:Guizhi Fuling Capsules can effectively reduce levels of tumor markers and inflammatory mediators in patients with early endometrial cancer after laparoscopy，promote postoperative recovery，and improve the clinical remission rate.